Related Experiment Video

Updated: Aug 14, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Low aspirin use in diabetics

Daad H Akbar1, Maimona M Ahmed, Aisha M Siddique

  • 1Department of Medicine, King Abdulaziz University Hospital, PO Box 18298, Jeddah 21415, Kingdom of Saudi Arabia. daadakb@yahoo.com

Saudi Medical Journal
|April 16, 2002
PubMed

Insights

Aspirin use is low among diabetic patients with cardiovascular disease or risk factors. This study found no significant differences in aspirin use between males and females, or Saudis and non-Saudis, highlighting a need for increased physician adoption.

Area of Science:

  • Cardiology and Diabetes Mellitus Research
  • Public Health and Preventive Medicine

Background:

  • Cardiovascular disease (CVD) is a major complication in patients with diabetes mellitus.
  • Aspirin is recommended for primary and secondary prevention of CVD in diabetic patients.
  • Current aspirin utilization patterns in this population require investigation.

Purpose of the Study:

  • To ascertain the prevalence of aspirin use in adult diabetics with established CVD or CVD risk factors.
  • To examine demographic variations in aspirin use, specifically comparing males and females, and Saudi and non-Saudi populations.

Main Methods:

  • Retrospective analysis of medical records from King Abdulaziz University Hospital (1998-2000).
  • Data collected included patient demographics, diabetes status, CVD history, CVD risk factors (hypertension, hyperlipidemia, obesity, smoking, family history), and aspirin usage.
  • Statistical analysis was performed to identify trends and significant differences.

Main Results:

  • Out of 550 diabetic patients, aspirin use was significantly higher in those with CVD (63%) compared to those without (12%).
  • Aspirin use was 29% in males versus 22% in females, and 24% in Saudis versus 27% in non-Saudis, with no statistically significant differences.
  • Overall aspirin use was found to be low in the studied diabetic population with CVD or risk factors.

Conclusions:

  • Aspirin use is suboptimal in diabetic patients with cardiovascular disease and/or risk factors.
  • There are no significant demographic disparities in aspirin use based on sex or nationality.
  • Increased physician emphasis on prescribing aspirin for primary and secondary CVD prevention in diabetics is warranted.
Abstract

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...